

29th January, 2021

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
---	--

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with Schedule III of Listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 29th January, 2021, *inter-alia*, have approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2020 and the Limited Review Report issued by B S R & Co. LLP., Statutory Auditors of the Company.

Pursuant to Regulation 33 of the Listing Regulations, we wish to enclose the following:

1. Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2020; and Limited Review Report issued by B S R & Co. LLP., Statutory Auditors of the Company,
2. A copy of the Press Release proposed to be issued in respect of the said Financial Results; and
3. Extract of Unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2020, being published in the Newspapers.

The meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 1.20 p.m.

Kindly take the same on record please.

Thanking you,

For **Wockhardt Limited**



Gajanand Sahu
Company Secretary

Encl: As above



BSR & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010


Limited Review Report on Unaudited Quarterly and Year to Date Standalone Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Wockhardt Limited ("the Company") for the quarter ended 31 December 2020 and year to date results for the period from 1 April 2020 to 31 December 2020 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **BSR & Co. LLP**
Chartered Accountants

Firm's Registration No: 101248W/W-100022



Koosai Lehery
Partner

Membership No: 112399

UDIN: 21112399AAAAAF9862

Place: Mumbai
Date: 29 January 2021

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
CIN:L24230MH1999PLC120720

Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id : investorrelations@wockhardt.com; Website: www.wockhardt.com

(Rs. In Crore except per share data)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

PARTICULARS	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	9 MONTHS ENDED	9 MONTHS ENDED	YEAR ENDED
	31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
(Refer notes below)	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income from Continuing Operations						
(a) Revenue from Continuing operations	252.97	294.96	208.17	725.51	727.84	890.06
(b) Other income	9.72	14.96	19.77	34.42	30.39	43.02
Total income	262.69	309.92	227.94	759.93	758.23	933.08
2 Expenses from Continuing Operations						
(a) Cost of materials consumed	77.07	106.33	53.15	194.08	171.38	236.70
(b) Purchase of stock-in-trade	45.63	30.21	17.70	126.27	59.55	85.20
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(35.78)	(6.81)	17.12	(27.74)	23.65	(8.61)
(d) Employee benefits expense	77.44	75.59	76.13	235.11	254.75	325.46
(e) Finance costs	49.20	46.97	51.55	154.78	162.12	220.17
(f) Depreciation and amortisation expense	42.72	42.97	43.78	131.77	128.91	173.39
(g) Exchange fluctuation loss / (gain), net	8.04	19.31	(3.60)	30.65	(11.98)	(42.80)
(h) Other expenses	88.63	82.64	100.02	283.06	303.34	427.25
Total expenses	352.95	397.21	355.85	1,127.98	1,091.72	1,416.76
3 Loss before exceptional items and tax from Continuing Operations (1-2)	(90.26)	(87.29)	(127.91)	(368.05)	(333.49)	(483.68)
4 Discontinued Operations						
Profit before exceptional items and tax from Discontinued Operations	-	-	41.05	13.87	114.93	145.36
5 Exceptional items- credit/(charge)						
a) Continuing Operations- Refer note 3	-	-	-	(142.48)	-	-
b) Discontinued Operations- Refer note 2	-	-	-	1,470.32	-	-
Total- Exceptional items	-	-	-	1,327.84	-	-
6 Loss after exceptional items before tax from Continuing Operations (3 ± 5a)	(90.26)	(87.29)	(127.91)	(510.53)	(333.49)	(483.68)
7 Tax expense of continuing operations :						
Current tax - credit	(22.16)	(16.39)	(14.33)	(108.44)	(40.15)	(50.80)
Tax pertaining to earlier years	-	-	3.69	-	3.69	3.69
Deferred tax - (credit)/charge	0.57	(13.52)	(20.71)	(57.10)	(69.55)	(110.89)
8 Net Loss from Continuing Operations (6 ± 7)	(68.57)	(57.33)	(96.56)	(344.89)	(227.43)	(325.63)
9 Profit after exceptional items before tax from Discontinued Operations (4 ± 5b)	-	-	41.05	1,484.19	114.93	145.36
10 Tax expense of discontinued operations:						
Current tax - charge	-	-	14.33	311.49	40.15	50.80
Deferred tax - charge	-	-	-	187.37	-	-
11 Profit from Discontinued Operations (9 ± 10)	-	-	26.72	985.33	74.78	94.56
12 Profit / (Loss) for the period (8 ± 11)	(68.67)	(57.38)	(69.84)	640.34	(152.70)	(231.12)
13 Other Comprehensive Income						
- Continuing Operations						
i) Items that will not be reclassified to Profit or Loss - (charge)/credit (consisting of re-measurement of net defined benefit (liability)/asset)	1.51	1.00	(0.42)	4.56	(1.26)	6.02
ii) Income tax relating to items that will not be reclassified to Profit or Loss - (charge)/credit	(0.53)	(0.35)	0.09	(1.59)	0.43	(2.10)
iii) Other Comprehensive Income (net of tax) from continuing operations	0.98	0.65	(0.33)	2.97	(0.83)	3.92
- Discontinued Operations						
i) Items that will not be reclassified to Profit or Loss - (charge)/credit (consisting of re-measurement of net defined benefit (liability)/asset)	-	-	(0.04)	(0.04)	(0.13)	(0.17)
ii) Income tax relating to items that will not be reclassified to Profit or Loss - (charge)/credit	-	-	0.02	0.01	0.05	0.06
iii) Other Comprehensive Income (net of tax) from discontinued operations	-	-	(0.02)	(0.03)	(0.08)	(0.11)
Total Comprehensive Income [12 ± 13a(iii) ± 13b(iii)]	(67.69)	(56.73)	(70.19)	643.28	(153.61)	(227.31)
14 Paid-up equity share capital (face value of Rs. 5/- each)	55.39	55.38	55.37	55.39	55.37	55.37
15 Other Equity excluding Revaluation Reserves as per balance sheet						939.25
16 Earnings per share for continuing operations (face value of Rs. 5/- each)						
(*not annualised)						
(a) Basic (Rs.)	(6.20)*	(5.18)*	(8.72)*	(31.15)*	(20.54)*	(29.42)
(b) Diluted (Rs.)	(6.20)*	(5.18)*	(8.72)*	(31.15)*	(20.54)*	(29.42)
Earnings per share for discontinued operations (face value of Rs. 5/- each)						
(*not annualised)						
(a) Basic (Rs.)	-	-	2.41*	88.97*	6.75*	8.54
(b) Diluted (Rs.)	-	-	2.40*	88.60*	6.72*	8.50
Earnings per share for continuing and discontinued operations (face value of Rs. 5/- each)						
(*not annualised)						
(a) Basic (Rs.)	(6.20)*	(5.18)*	(6.31)*	57.82*	(13.79)*	(20.88)
(b) Diluted (Rs.)	(6.20)*	(5.18)*	(6.31)*	57.58*	(13.79)*	(20.88)

Notes To Standalone Results :-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on January 29, 2021. The results have been subjected to limited review by the Statutory Auditors of the Company.
- 2) The Board of Directors, in their meeting held on June 09, 2020, concluded the Business transfer agreement ("BTA") entered into between the Company and Dr. Reddy's Laboratories Limited ("Purchaser") dated February 12, 2020 read with amendments made time to time for the transfer of the business comprising 62 products and line extensions along with related assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives, and the manufacturing facility at Baddi, Himachal Pradesh, where some of the products which are being transferred were manufactured (together the "Business Undertaking"), to the Purchaser. The consideration for the above said transfer of Business Undertaking for Rs. 1,850 crore was structured as per following :
 - a) an amount equal to Rs. 1,550 crore (including a deposit of Rs. 67 crore in escrow account towards adjustments for, inter alia, Net working capital, employee liabilities and certain other contractual and statutory liabilities) to be paid on the Closing Date under the BTA. The said amount has been paid by the Purchaser to the Company during the period ended December 31, 2020 including release of Rs. 63 crore out of the original escrow account of Rs.67 crore and,
 - b) balance amount equal to Rs. 300 crore out of total consideration of Rs. 1,850 crore has been held back ("Holdback Amount"), by the Purchaser on the Closing Date (i.e., June 09, 2020) for assessment of the impact of the COVID-19 pandemic on the Business Undertaking and shall be released as equal to 2 (two) times the amount by which the revenue exceeds Rs. 480 crore from sales of the products forming part of the said Business Undertaking by the Purchaser during the 12 months post-closing date.

The profit from aforesaid Transfer of Business Undertaking (excluding the Holdback Amount of Rs. 300 crore) amounting to Rs. 1,470.32 crore has been shown as 'Exceptional Items - discontinued operations'.
- 3) During the period ended December 31, 2020, the Company reassessed the commercial prospects of the Nutrition Business and decided not to pursue it in near future and therefore, the Nutrition Business assets were classified as assets held for disposal and an impairment loss of Rs. 142.48 crore has been recognised under the head 'Exceptional items - continuing operations'.
- 4) The Company continues to monitor the impact of COVID-19 on its businesses across the globe, its customers, vendors, employees, productions, supply chain and logistics etc. The Company has exercised due care in significant accounting judgements and estimates in relation to recoverability of receivables, investments and inventories based on the information available to date, both internal and external, while preparing the Company's financial results for the current period.
- 5) During the quarter ended December 31, 2020, the Company has allotted 20,000 (Year to date 41,950) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options.
- 6) The Company is exclusively into Pharmaceutical business Segment.
- 7) Previous period / year figures have been recast / re-grouped to conform to the current period's presentation.

Mumbai

Date : January 29, 2021

FOR WOCKHARDT LIMITED



H F KHORAKIWALA

CHAIRMAN

DIN: 00045608



B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of
Wockhardt Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Wockhardt Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 31 December 2020 and year to date results for the period from 1 April 2020 to 31 December 2020 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the financial information of the following entities:

Name of the Entity	Relationship
1) Wockhardt UK Holdings Limited (including its following subsidiaries and its step-down subsidiaries) a) Wallis Group Limited b) The Wallis Laboratory Limited c) Wallis Licensing Limited d) Wockhardt Farmaceutica Do Brasil Ltda	Wholly Owned Subsidiary

Limited Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

Wockhardt Limited

Name of the Entity	Relationship
2) Wockhardt Infrastructure Development Limited	Wholly Owned Subsidiary
3) Wockhardt Europe Limited (including its following wholly owned subsidiary) a) Wockhardt Nigeria Limited	Wholly Owned Subsidiary
4) Wockhardt Medicines Limited	Wholly Owned Subsidiary
5) Wockhardt Bio AG (including its following subsidiaries and its step-down subsidiaries) a) CP Pharmaceuticals Limited b) CP Pharma (Schweiz) AG c) Z & Z Services GmbH d) Wockhardt UK Limited e) Wockpharma Ireland Limited f) Pinewood Laboratories Limited g) Pinewood Healthcare Limited h) Laboratories Negma S.A.S. i) Wockhardt France (Holdings) S.A.S. j) Wockhardt Holding Corp. k) Wockhardt USA LLC l) Morton Grove Pharmaceuticals Inc. m) MGP Inc. n) Laboratories Pharma 2000 S.A.S. o) Niverpharma S.A.S. p) Negma Beneulex S.A. q) Phytex S.A.S. r) Wockhardt Farmaceutica SA DE CV s) Wockhardt Services SA DE CV t) Wockhardt Bio (R) LLC u) Wockhardt Bio Pty Limited v) Wockhardt Bio Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Limited Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)


Wockhardt Limited

6. We did not review the interim financial information of four subsidiaries included in the Statement, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs 807.80 crores and Rs 2,157.90 crores, total net profit after tax (before consolidation adjustments) of Rs 92.64 crores and Rs 429.91 crores and total comprehensive income (before consolidation adjustments) of Rs 92.33 crores and Rs 428.18 crores, for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020, respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matter.
7. The Statement includes the interim financial information of sixteen subsidiaries which have not been reviewed, whose interim financial information reflect total revenue (before consolidation adjustments) of Rs 19.60 crores and Rs 48.05 crores, total net profit after tax (before consolidation adjustments) of Rs 4.71 crores and Rs 11.18 crores and total comprehensive income (before consolidation adjustments) of Rs 4.71 crores and Rs 11.18 crores for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020, respectively, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial information are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For BSR & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022



Koosai Leheri

Partner

Membership No: 112399

ICAI UDIN: 21112399AAAAAE6165

Mumbai

29 January 2021

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CIN: L24230MH1999PLC120720

Tel: 91 22 2653 4444; Fax: 91 22 2652 3605; e-mail: investorrelations@wockhardt.com, Website: www.wockhardt.com

(Rs. in Crore except per share data)						
STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020						
PARTICULARS	3 MONTHS ENDED 31/12/2020	3 MONTHS ENDED 30/09/2020	3 MONTHS ENDED 31/12/2019	9 MONTHS ENDED 31/12/2020	9 MONTHS ENDED 31/12/2019	YEAR ENDED 31/03/2020
(Refer Notes Below)	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income from Continuing Operations						
(a) Revenue from Continuing operations	764.02	714.05	748.60	2,076.34	2,157.05	2,843.99
(b) Other income	100.54	16.24	17.20	124.73	25.08	38.81
Total income	864.56	730.29	765.80	2,201.07	2,182.13	2,882.80
2 Expenses from Continuing Operations						
(a) Cost of materials consumed	176.21	217.32	146.65	510.52	441.42	621.72
(b) Purchase of stock-in-trade	184.27	127.36	126.43	470.70	390.98	507.70
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(45.54)	(51.69)	45.52	(155.00)	92.38	74.03
(d) Employee benefits expense	201.84	197.37	178.53	601.70	567.99	743.33
(e) Finance costs	59.85	60.90	78.73	194.45	214.29	275.74
(f) Depreciation and amortisation expense	67.88	57.15	56.22	180.99	163.26	224.14
(g) Exchange fluctuation loss / (gain), net	(2.59)	10.59	(25.06)	16.66	(13.83)	(21.27)
(h) Other expenses	191.45	196.40	183.41	628.73	572.56	799.45
Total expenses	833.37	815.40	790.43	2,448.75	2,429.05	3,224.84
3 Profit/ (Loss) before exceptional items and tax from Continuing Operations (1-2)	31.19	(85.11)	(24.63)	(247.68)	(246.92)	(342.04)
4 Discontinued Operations						
Profit before exceptional items and tax from Discontinued Operations	-	-	41.05	13.87	114.93	145.36
5 Exceptional Items- credit/(charge)						
a) Continuing Operations- (Refer note 4)	-	-	-	(142.48)	-	-
b) Discontinued Operations- (Refer note 3)	-	-	-	1,470.32	-	-
Total Exceptional Items	-	-	-	1,327.84	-	-
6 Profit/ (Loss) after exceptional items before tax from Continuing Operations (3 ± 5a)	31.19	(85.11)	(24.63)	(390.16)	(246.92)	(342.04)
7 Tax expense of continuing operations :						
Current tax - credit	(10.12)	(12.17)	(3.56)	(88.41)	(23.66)	(48.42)
Tax pertaining to earlier years	-	-	3.69	-	3.69	3.69
Deferred tax - (credit)/ charge	8.91	(76.23)	(17.25)	(111.86)	(40.26)	(159.36)
8 Net Profit / (Loss) from Continuing Operations (6 ± 7)	32.40	3.29	(7.51)	(189.89)	(186.69)	(137.95)
9 Profit after exceptional items before tax from Discontinued Operations (4 ± 5b)	-	-	41.05	1,484.19	114.93	145.36
10 Tax expense of discontinued operations:						
Current tax - charge	-	-	14.33	311.49	40.15	50.80
Deferred tax - charge	-	-	-	167.37	-	-
11 Profit from Discontinued Operations (9 ± 10)	-	-	26.72	985.33	74.78	94.56
12 Profit / (Loss) for the period (8 ± 11)	32.40	3.29	19.21	795.44	(111.91)	(43.39)
Attributable to:						
Equity shareholders of the Company	15.24	3.55	9.63	778.85	(117.52)	(69.22)
Non - Controlling Interest	17.16	(0.26)	9.58	16.59	5.61	25.83
13 Other Comprehensive Income from Continuing Operations						
(a) Items that will not be reclassified to Profit or Loss - (charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset)	1.14	0.51	(5.00)	2.77	(13.14)	(2.95)
(b) Income tax relating to items that will not be reclassified to Profit or Loss - (charge) / credit	(0.46)	(0.25)	0.93	(1.25)	2.50	(3.45)
(c) Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations)	41.10	(4.77)	50.55	50.40	50.18	107.38
(d) Other Comprehensive income from continuing operations (net of tax) (a ± b ± c)	41.78	(4.51)	46.48	51.92	39.54	100.98
14 Other Comprehensive Income from Discontinued Operations						
(a) Items that will not be reclassified to Profit or Loss - (charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset)	-	-	(0.04)	(0.04)	(0.13)	(0.17)
(b) Income tax relating to items that will not be reclassified to Profit or Loss - (charge) / credit	-	-	0.02	0.01	0.05	0.06
(c) Other Comprehensive Income from discontinued operations (net of tax) (a ± b)	-	-	(0.02)	(0.03)	(0.08)	(0.11)
15 Total Comprehensive Income (12 ± 13 (d) ± 14 (c))	74.18	(1.22)	65.67	847.33	(72.45)	57.48
Attributable to:						
Equity shareholders of the Company	65.03	(0.89)	49.48	835.99	(63.77)	1.52
Non - Controlling Interest	9.15	(0.33)	16.19	11.34	11.32	55.96
16 Paid-up equity share capital (face value of Rs. 5/- each)	55.39	55.38	55.37	55.39	55.37	55.37
17 Other Equity excluding Revaluation Reserves as per Balance Sheet						2,616.30
18 Earnings per equity share for continuing operations (face value of Rs. 5/- each) (*not annualised)						
(a) Basic (Rs.)	1.38*	0.32*	(1.54)*	(18.64)*	(17.37)*	(14.79)
(b) Diluted (Rs.)	1.37*	0.32*	(1.54)*	(18.64)*	(17.37)*	(14.79)
Earnings per equity share for discontinued operations (face value of Rs. 5/- each) (*not annualised)						
(a) Basic (Rs.)	0*	0*	2.41*	88.97*	6.75*	8.54
(b) Diluted (Rs.)	0*	0*	2.40*	88.60*	6.72*	8.50
Earnings per equity share for continuing and discontinued operations (face value of Rs. 5/- each) (*not annualised)						
(a) Basic (Rs.)	1.38*	0.32*	0.87*	70.33*	(10.61)*	(6.25)
(b) Diluted (Rs.)	1.37*	0.32*	0.87*	70.03*	(10.61)*	(6.25)

Notes To Consolidated Results:-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on January 29, 2021. The results have been subjected to limited review by the Statutory Auditors of the Company.
- 2) The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute 'the Group') and are prepared by applying Ind AS 110 - "Consolidated Financial Statements".
- 3) The Board of Directors, in their meeting held on June 09, 2020, concluded the Business transfer agreement ("BTA") entered into between the Company and Dr. Reddy's Laboratories Limited ("Purchaser") dated February 12, 2020 read with amendments made time to time for the transfer of the business comprising 62 products and line extensions along with related assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives, and the manufacturing facility at Baddi, Himachal Pradesh, where some of the products which are being transferred were manufactured (together the "Business Undertaking"), to the Purchaser. The consideration for the above said transfer of Business Undertaking for Rs. 1,850 crore was structured as per following :
 - a) an amount equal to Rs. 1,550 crore (including a deposit of Rs. 67 crore in escrow account towards adjustments for, inter alia, Net working capital, employee liabilities and certain other contractual and statutory liabilities) to be paid on the Closing Date under the BTA. The said amount has been paid by the Purchaser to the Company during the period ended December 31, 2020 including release of Rs. 63 crore out of the original escrow account of Rs. 67 crore and,
 - b) balance amount equal to Rs. 300 crore out of total consideration of Rs. 1,850 crore has been held back ("Holdback Amount"), by the Purchaser on the Closing Date (i.e., June 09, 2020) for assessment of the impact of the COVID-19 pandemic on the Business Undertaking and shall be released as equal to 2 (two) times the amount by which the revenue exceeds Rs. 480 crore from sales of the products forming part of the said Business Undertaking by the Purchaser during the 12 months post-closing date.

The profit from aforesaid Transfer of Business Undertaking (excluding the Holdback Amount of Rs. 300 crore) amounting to Rs. 1,470.32 crore has been shown as ' Exceptional Items - discontinued operations'.
- 4) During the period ended December 31, 2020, the Company reassessed the commercial prospects of the Nutrition Business and decided not to pursue it in near future and therefore, the Nutrition Business assets were classified as assets held for disposal and an impairment loss of Rs. 142.48 crore has been recognised under the head 'Exceptional items - continuing operations'.

5) Key Financials on Standalone basis:

(Rs. in Crore)

PARTICULARS	3 MONTHS ENDED 31/12/2020	3 MONTHS ENDED 30/09/2020	3 MONTHS ENDED 31/12/2019	9 MONTHS ENDED 31/12/2020	9 MONTHS ENDED 31/12/2019	YEAR ENDED 31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income (continuing operation)	262.69	309.92	227.94	759.93	758.23	933.08
Loss before tax from continuing operation	(90.26)	(87.29)	(127.91)	(510.53)	(333.49)	(483.68)
Loss after tax from continuing operation	(68.67)	(57.38)	(96.56)	(344.99)	(227.48)	(325.68)
Profit before tax from discontinued operation	-	-	41.05	1,484.19	114.93	145.36
Profit after tax from discontinued operation	-	-	26.72	985.33	74.78	94.56

Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com) and also on the Company's website www.wockhardt.com.

- 6) The Group continues to monitor the impact of COVID-19 on its businesses across the globe, its customers, vendors, employees, productions, supply chain and logistics etc. The Group has exercised due care in significant accounting judgements and estimates in relation to recoverability of receivables, investments and inventories based on the information available to date, both internal and external, while preparing the Group's financial results for the current period.
- 7) During the quarter ended December 31, 2020, the Company has allotted 20,000 (Year to date 41,950) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options.
- 8) The Group is exclusively into Pharmaceutical business Segment.
- 9) For List of Subsidiaries as on December 31, 2020 please refer Annexure.
- 10) Previous period / year figures have been recast / re-grouped to conform to the current period's presentation.

Mumbai
Date : January 29, 2021

FOR WOCKHARDT LIMITED

H F KHORAKIWALA
CHAIRMAN
DIN: 00045608



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Annexure to Note 9 of Consolidated Unaudited Results for the Quarter and Nine Months ended December 31, 2020

List of Subsidiaries as on December 31, 2020

- 1 Wockhardt UK Holdings Limited
- 2 CP Pharmaceuticals Limited
- 3 CP Pharma (Schweiz) AG
- 4 Wallis Group Limited
- 5 The Wallis Laboratory Limited
- 6 Wockhardt Farmaceutica Do Brasil Ltda
- 7 Wallis Licensing Limited
- 8 Wockhardt Infrastructure Development Limited
- 9 Z & Z Services GmbH
- 10 Wockhardt Europe Limited
- 11 Wockhardt Nigeria Limited
- 12 Wockhardt USA LLC
- 13 Wockhardt UK Limited
- 14 Wockpharma Ireland Limited
- 15 Pinewood Laboratories Limited
- 16 Pinewood Healthcare Limited
- 17 Laboratoires Negma S.A.S.
- 18 Wockhardt France (Holdings) S.A.S.
- 19 Wockhardt Holding Corp.
- 20 Morton Grove Pharmaceuticals Inc.
- 21 MGP Inc.
- 22 Laboratoires Pharma 2000 S.A.S.
- 23 Niverpharma S.A.S.
- 24 Negma Beneulex S.A.
- 25 Phytex S.A.S.
- 26 Wockhardt Farmaceutica SA DE CV
- 27 Wockhardt Services SA DE CV
- 28 Wockhardt Bio AG
- 29 Wockhardt Bio (R) LLC
- 30 Wockhardt Bio Pty Limited
- 31 Wockhardt Bio Limited
- 32 Wockhardt Medicines Limited



Mumbai, 29th January, 2021

Wockhardt's profitability (PAT) for Q3FY21 at Rs.15 crore

	Q3 FY21	Q2 FY21	Q3 FY20	9M FY21	9M FY20
	Oct - Dec 2020	Jul - Sep 2020	Oct - Dec 2019	Apr - Dec 2020	Apr - Dec 2019
	INR Cr	INR Cr	INR Cr	INR Cr	INR Cr
Sales	764	714	869	2,130	2,534
EBITDA before R&D*	97	72	154	158	373
EBITDA % to Sales	12.7%	10.1%	17.7%	7.4%	14.7%
R&D	42	45	45	124	165
R&D % to Sales	5.4%	6.3%	5.2%	5.8%	6.5%
EBITDA *	56	27	109	34	208
EBITDA Margins %	7.3%	3.8%	12.5%	1.6%	8.2%
Exceptional Items #	-	-	-	1,328	-
PBT	31	(85)	16	1,094	(132)
Profit After Tax	15	4	9	779	(117)
PAT Margins %	2.0%	0.5%	1.1%	36.6%	-4.6%
EPS (Rs)	1.4	0.3	0.9	70.3	(10.6)

*Inclusive of impact of IND AS 116 (Lease Accounting).

Exceptional Items includes Profit in connection with the transfer of the business comprising 62 products and line extensions along with related assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives, and the manufacturing facility at Baddi, Himachal Pradesh (together the "Business Undertaking"), to Dr. Reddy's Laboratories Limited ("DRL") which was completed in Q1FY21.

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 3rd Quarter Results for Financial Year 2020-21, today.

The Company has reported EBITDA of Rs.56 crore (as compared to Rs.27 crore in the previous quarter i.e Q2FY21) mainly driven by enhanced Revenue and Cost rationalisation. Profit after

Tax (PAT) for the Quarter was Rs.15 crore against a marginal profit of Rs.4 crore in the previous quarter. Profit after Tax (PAT) for 9MFY21 is reported at Rs.779 crore as against Loss of Rs.117 crore in the corresponding period.

Net Debt-Equity ratio as on 31st December, 2020 stood at 0.49 (31st March, 2020 stood at 0.84).

Wockhardt UK hosts visit of Prime Minister of UK

On 30th November 2020, Wockhardt hosted a visit at its Wrexham facility in North Wales of the Prime Minister of the United Kingdom, Mr. Boris Johnson.

The UK Government has reserved one fill and finish production line at Wockhardt UK for its exclusive use in order to guarantee the supply of vaccines required to fight against COVID-19.

As per the terms of the agreement the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID-19, including AZD1222, the vaccine co-invented by the University of Oxford and its spin-out company, Vaccitech, and licensed by AstraZeneca.

In the UK, Wockhardt is one of the largest suppliers into the NHS for over 20 years, has had a presence in Wrexham for over two decades and employs over 400 people at its 612,000 square feet high-tech manufacturing facility.

Business Review:

Quarter ended 30th December, 2020:

- **UK Business** during the quarter stood at Rs.301 crore in Q3FY21 (PY Rs.219 crore) showing a growth of 38%. UK Business contributed about 39% of Global Revenue.
- **Emerging Markets Business** of the Company stood at Rs.128 crore in Q3FY21 (PY Rs.138 crore). Emerging Markets Business contributed about 17% of the Global Revenue.
- **India Business** (both Continued & Discontinued Operations) stood at Rs.122 crore in Q3FY21 as compared to Rs.235 crore in Q3FY20. The Continuing Business stood at Rs.122 in Q3FY21 (PY Rs.114 crore) registering growth of 7%. India Business contributed 16% of the Global Revenue.

- **Irish Business** stood at Rs.46 crore in Q3FY21 (PY Rs.38 crore) showing a growth of 23%.
- **US Business** stood at Rs.135 crore in Q3FY21 as compared to Rs.213 crore in Q3FY20. US Business contributed 18% of the Global Revenue.

Research & Development expenditure during the quarter was at Rs.42 crore (5% to sales) and including capital expenditure is at 9% to sales.

Capital expenditure during the quarter was Rs.27 crore.

9 Months ended 30th December, 2020:

- **UK Business** stood at Rs.752 crore in 9MFY21 (PY Rs.666 crore) recording a 13% growth. UK Business contributed about 35% of Global Revenue.
- **Emerging Markets Business** of the Company stood at Rs.435 crore in 9MFY21 (PY Rs.414 crore) showing a growth of 5%. Emerging Markets Business contributed about 20% of the Global Revenue.
- **India Business** stood at Rs.362 crore in 9MFY21 as compared to Rs.706 crore in 9MFY20. Continued operations of the India Business stood at Rs.308 crore (PY Rs.328 crore). De-growth is mainly on account of lower sales in Quality Generics division and in some of the therapeutic areas. India Business continued operations contributed to 14% of the Global Revenue.
- **Irish Business** stood at Rs.113 crore in 9MFY21 (PY Rs.114 crore).
- **US Business** stood at Rs.349 crore in 9MFY21 as compared to Rs.544 crore in 9MFY20. US Business contributed 16% of the Global Revenue.

Research & Development expenditure during 9 Months ended 30th December, 2020 was at Rs.124 crore (6% to sales) and including capital expenditure is at 9% to sales.

Capital expenditure during the nine-month period ended 31st December, 2020 was Rs.71 crore.

Intellectual Property (IP):

9 patents were filed during the quarter ended 31st December, 2020 and the cumulative filings till date are 3182. The company was granted 10 patents during the quarter and now holds 752 patents.

About Wockhardt:

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing over 5000 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.

Extract of Unaudited Consolidated Financial Results
For the Quarter and Nine months ended December 31, 2020

(Rs. In Crore except per share data)

Particulars	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	9 MONTHS ENDED	9 MONTHS ENDED	YEAR ENDED
	31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income from Continuing Operations	864.56	730.29	765.80	2,201.07	2,182.13	2,882.80
Profit/ (Loss) before exceptional items and tax from Continuing Operations	31.19	(85.11)	(24.63)	(247.68)	(246.92)	(342.04)
Net Profit / (Loss) after tax from continuing operations	32.4	3.29	(7.51)	(189.89)	(186.69)	(137.95)
Net Profit/(Loss) from discontinued operations after tax	-	-	26.72	985.33	74.78	94.56
Net Profit / (Loss) after tax	32.4	3.29	19.21	795.44	(111.91)	(43.39)
Total Comprehensive Income (Continuing and discontinued operations) (Comprising of Profit / (Loss) after tax and Other Comprehensive Income after tax)	74.18	(1.22)	65.67	847.33	(72.45)	57.48
Paid-up Equity Share Capital (Face value of Rs. 5/- each)	55.39	55.38	55.37	55.39	55.37	55.37
Other Equity excluding Revaluation Reserves as shown in the audited Balance Sheet						2,616.30
Earnings per share (Face value of Rs 5/- each) * Not annualised (Continuing and discontinued operations)						
Basic Rs.	1.38*	0.32*	0.87*	70.33*	(10.61)*	(6.25)
Diluted Rs.	1.37*	0.32*	0.87*	70.03*	(10.61)*	(6.25)

Notes:

1. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on January 29, 2021. The results have been subjected to limited review by the Statutory Auditors of the Company.

2. Information on Standalone Financial Results are as follows:

Particulars	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	9 MONTHS ENDED	9 MONTHS ENDED	YEAR ENDED
	31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income (continuing operation)	262.69	309.92	227.94	759.93	758.23	933.08
Loss before tax from continuing operation	(90.26)	(87.29)	(127.91)	(510.53)	(333.49)	(483.68)
Loss after tax from continuing operation	(68.67)	(57.38)	(96.56)	(344.99)	(227.48)	(325.68)
Profit before tax from discontinued operation	-	-	41.05	1,484.19	114.93	145.36
Profit after tax from discontinued operation	-	-	26.72	985.33	74.78	94.56

3. The above is an extract of the detailed format of the Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results are available on the websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com) and on the Company's website (www.wockhardt.com).

FOR WOCKHARDT LIMITED



H F KHOKAKIWALA
CHAIRMAN
DIN: 00045608

Mumbai
Date : January 29, 2021